HK1212599A1 - 重構的 配製劑 - Google Patents

重構的 配製劑

Info

Publication number
HK1212599A1
HK1212599A1 HK16100504.1A HK16100504A HK1212599A1 HK 1212599 A1 HK1212599 A1 HK 1212599A1 HK 16100504 A HK16100504 A HK 16100504A HK 1212599 A1 HK1212599 A1 HK 1212599A1
Authority
HK
Hong Kong
Prior art keywords
hdl
formulation
reconstituted
reconstituted hdl
hdl formulation
Prior art date
Application number
HK16100504.1A
Other languages
English (en)
Inventor
Yvonne Vucica
Gary Lee Warren
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of HK1212599A1 publication Critical patent/HK1212599A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK16100504.1A 2012-11-02 2016-01-18 重構的 配製劑 HK1212599A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261721771P 2012-11-02 2012-11-02
EP13153903 2013-02-04
US13/803,863 US9125943B2 (en) 2012-11-02 2013-03-14 Reconstituted HDL formulation
AU2013205684A AU2013205684B2 (en) 2012-11-02 2013-04-10 Reconstituted hdl formulation
PCT/AU2013/001260 WO2014066943A1 (en) 2012-11-02 2013-10-31 Reconstituted hdl formulation

Publications (1)

Publication Number Publication Date
HK1212599A1 true HK1212599A1 (zh) 2016-06-17

Family

ID=47665977

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100504.1A HK1212599A1 (zh) 2012-11-02 2016-01-18 重構的 配製劑

Country Status (16)

Country Link
US (5) US9125943B2 (zh)
EP (2) EP3502131A1 (zh)
JP (1) JP6340372B2 (zh)
KR (1) KR102263810B1 (zh)
CN (2) CN108057023B (zh)
AU (1) AU2013205684B2 (zh)
BR (1) BR112015009748B1 (zh)
CA (1) CA2889785C (zh)
HK (1) HK1212599A1 (zh)
IL (1) IL238504B (zh)
MX (1) MX364587B (zh)
NZ (1) NZ631131A (zh)
PL (1) PL2916857T3 (zh)
RU (1) RU2669568C2 (zh)
SG (1) SG11201503083UA (zh)
WO (1) WO2014066943A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201903209T4 (tr) 2010-06-30 2019-03-21 Csl Ltd Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi.
US9125943B2 (en) * 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
CN110172093A (zh) * 2013-06-05 2019-08-27 杰特有限公司 制备载脂蛋白a-i的方法
EP3418290A1 (en) 2013-08-08 2018-12-26 CSL Ltd. Contaminant removal method
EP3490579A1 (en) 2016-07-27 2019-06-05 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
US20200038481A1 (en) * 2016-11-10 2020-02-06 Csl Limited Reconstituted high density lipoprotein treatment of myocardial infarction
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
PL372925A1 (en) 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
CA2486127C (en) 2002-05-17 2014-03-11 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
IL165253A0 (en) 2002-05-17 2005-12-18 Esperion Therapeutics Inc Methods and compositions for the treatment of ischemic reperfusion
PE20050438A1 (es) 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
KR100992488B1 (ko) 2006-12-29 2010-11-05 주식회사 녹십자 ＡｐｏＡ-Ｉ의 정제방법 및 정제된ＡｐｏＡ-Ｉ을 이용한재구축 ＨＤＬ의 생산 방법
SG183743A1 (en) 2007-08-17 2012-09-27 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
US8734853B2 (en) 2008-11-17 2014-05-27 University Of North Texas Health Science Center At Fort Worth HDL particles for delivery of nucleic acids
TR201903209T4 (tr) 2010-06-30 2019-03-21 Csl Ltd Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi.
PL2767546T3 (pl) * 2011-02-07 2019-04-30 Cerenis Therapeutics Holding Sa Kompleksy lipoproteinowe i ich wytwarzanie oraz ich zastosowania
US9125943B2 (en) * 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation

Also Published As

Publication number Publication date
IL238504A0 (en) 2015-06-30
RU2669568C2 (ru) 2018-10-12
US20200397859A1 (en) 2020-12-24
AU2013205684B2 (en) 2015-08-20
CN104755096B (zh) 2017-10-13
US20140221272A1 (en) 2014-08-07
US20150306176A1 (en) 2015-10-29
RU2015120808A (ru) 2016-12-20
PL2916857T3 (pl) 2019-06-28
EP2916857B1 (en) 2019-01-16
MX2015004546A (es) 2015-07-14
JP6340372B2 (ja) 2018-06-06
NZ631131A (en) 2015-12-24
KR20150079947A (ko) 2015-07-08
AU2013205684A1 (en) 2014-05-22
CN108057023B (zh) 2022-02-08
CN108057023A (zh) 2018-05-22
EP2916857A4 (en) 2016-05-25
CA2889785C (en) 2022-07-19
SG11201503083UA (en) 2015-05-28
US10603355B2 (en) 2020-03-31
WO2014066943A1 (en) 2014-05-08
BR112015009748B1 (pt) 2021-04-27
EP2916857A1 (en) 2015-09-16
BR112015009748A2 (pt) 2017-07-11
CA2889785A1 (en) 2014-05-08
US11464828B2 (en) 2022-10-11
EP3502131A1 (en) 2019-06-26
US9125943B2 (en) 2015-09-08
IL238504B (en) 2018-02-28
US20230142696A1 (en) 2023-05-11
CN104755096A (zh) 2015-07-01
KR102263810B1 (ko) 2021-06-15
JP2015535263A (ja) 2015-12-10
MX364587B (es) 2019-05-02
US20190015476A1 (en) 2019-01-17
US11957731B2 (en) 2024-04-16
US9925236B2 (en) 2018-03-27

Similar Documents

Publication Publication Date Title
HK1203146A1 (zh) 抗體製劑
ZA201500212B (en) Progesterone formulations
PL3117837T3 (pl) Formulacje przeciwciała
PL2802209T3 (pl) Preparaty do uszu
GB201111438D0 (en) Formulation
ZA201309221B (en) Formulation
HK1212599A1 (zh) 重構的 配製劑
HK1202445A1 (zh) 新製劑
ZA201306000B (en) Stable formulation
HK1205679A1 (zh) 尼古丁製劑
ZA201402456B (en) Formulation
PT2662093E (pt) Formulação de tobramicina
EP2800474A4 (en) COFFEE FORMULATION
GB201106958D0 (en) Formulation
HUE042620T2 (hu) Rekonstituált HDL-készítmény
IL234771A0 (en) Nicotine formulation
GB201211247D0 (en) Improved formulation
GB201206178D0 (en) Formulations
SI2662093T1 (sl) Formulacija tobramicina
GB201104284D0 (en) Formulation